|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We also found that treatment with potassium channel inhibitors rescued behavioral abnormalities without rescuing MCT1 expression, suggesting that myelin disruption induces behavioral abnormalities independently of MCT1.
|
31290185 |
2019 |
|
Actinic cheilitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In a randomized controlled open trial, 37 patients aged 16-65 years diagnosed with schizophrenia-spectrum disorders were randomly assigned (1:1) to receive a single-session intervention designed to reduce the JTC bias (MCT-JTC; adapted from Metacognitive Training [MCT]) or an attention control (AC) condition designed to control for therapist attention, duration, modality, and face validity.
|
30260458 |
2019 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MCT1, MCT4 and mitochondrial cytochrome c oxidase (MTCO1) expression were determined with immunohistochemistry in esophageal specimens from 129 patients with columnar dysplasia or adenocarcinoma.
|
28206968 |
2017 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings combined with survival analysis of public datasets suggest that MCT1 and GLUT1 may be potential prognostic markers in adenocarcinoma and druggable targets in squamous cell carcinoma.
|
26539827 |
2015 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Consistently, FOXM1 expression is statistically associated with MCT1 positivity in SCC, whereas the expression of FOXO3a, a FOXM1 functional antagonist, is linked to MCT1 negativity in AC.
|
26563366 |
2016 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT1 and MCT4 are prognostic factors in esophageal adenocarcinoma.
|
28206968 |
2017 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> effects on extracellular flux via glycolysis and mitochondrial stress tests suggest that candidate compounds 3 and 9 disrupt glycolysis and OxPhos efficiently in MCT1 expressing colorectal adenocarcinoma WiDr and MCT4 expressing triple negative breast cancer MDA-MB-231 cells.
|
31040927 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma.
|
26539827 |
2015 |
|
Adult Burkitt Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, AZD3965 caused lactate accumulation in the Raji Burkitt's lymphoma model and significant tumor growth inhibition.
|
29050199 |
2017 |
|
Adult Burkitt Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a potential therapy for diffuse large B-cell lymphoma and Burkitt lymphoma.
|
28385782 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours.
|
30790227 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
|
29534146 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a potential therapy for diffuse large B-cell lymphoma and Burkitt lymphoma.
|
28385782 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.
|
19789340 |
2009 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We show that efflux of BCKAs, as well as pyruvate, is mediated by the monocarboxylate transporter 1 (MCT1) in glioblastoma.
|
29066459 |
2017 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that MCT1 is involved in the maintenance of GSCs and is a promising therapeutic target for glioblastoma.
|
26902636 |
2016 |
|
Adult Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Through bioinformatics analysis, the high expression of HIF-1α, MCT1 or MCT4 indicate a poor prognosis in glioblastoma.
|
29928884 |
2018 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The effect of CHC (MCT inhibitor) and MCT1 silencing was assessed in in vitro and in vivo glioblastoma models.
|
23258846 |
2013 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism <i>in vitro</i> and <i>in vivo</i> Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.
|
28923861 |
2017 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of SLC16A1 by siRNA induced cell death in medulloblastoma cells.
|
19427019 |
2009 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
|
30790227 |
2019 |
|
Adult Rickets
|
0.010 |
Biomarker
|
disease |
BEFREE |
We reviewed cases of tumour-associated osteomalacia or histologically definitive PMT-MCT without osteomalacia using histological, immunohistochemical and genetic methods and evaluated the diagnostic significance of these findings.
|
28858396 |
2018 |
|
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the context of this model, chances are that a new way is established in which NO can influence the pathogenesis of AD by down-regulating the expression of MCT1.
|
31326499 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Compared to control groups, the CD34<sup>+</sup>MCT was associated with lower total amputation (odds ratio (OR): 0.45, p=0.01; 95% confidence interval (CI): 0.24-0.85) and a higher complete ulcer healing rate (OR: 2.80, p=0.008; 95% CI: 1.31-6.02), but showed no advantage in major amputation (OR: 0.58, p=0.11; 95% CI: 0.29-1.14) and all-cause mortality (OR: 0.82, p=0.62; 95% CI: 0.36-1.83) .
|
29457540 |
2018 |
|
anaphylaxis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The magnitude of increase in acute MCT above the threshold predicted by consensus equation was higher in the anaphylaxis group compared to controls (P=.0001).
|
28609557 |
2017 |